Article

Sealed capsular irrigation system may help prevent posterior capsular opacification

A new sealed capsular irrigation system (PerfectCapsule, Milvella Pty. Ltd.) allows selective application of osmotic or pharmacologic agents in the capsular bag without affecting the surrounding tissue.

Paris—A new sealed capsular irrigation system (PerfectCapsule, Milvella Pty. Ltd.) allows selective application of osmotic or pharmacologic agents in the capsular bag without affecting the surrounding tissue.

Gerd Auffarth, MD, of the University of Heidelberg, Heidelberg, Germany, introduced the device at the annual meeting of the European Society of Cataract and Refractive Surgeons. The device is particularly useful in pediatric patients and patients undergoing clear lens extraction.

The system consists of a 7-mm silicon sealing device that can be applied on the anterior chamber with a capsulorhexis of 5 mm. Dr. Auffarth explained that the device has an irrigation line and an aspiration line to which a vacuum can be applied. After the capsular bag is sealed, it can be irrigated as desired with different substances.

In a prospective randomized trial, Dr. Auffarth and colleagues used the device in 19 patients (mean age, 69 years).

"In all patients, the system was used without complication," he said.

The investigators also found that the endothelial cell count was not adversely affected and corneal pachymetry did not differ from that of the patient's fellow control eye. The visual acuity developed normally over 3 months. There was a higher incidence of fibrosis and anterior capsule whitening in the control eyes compared with the eyes in which the sealed capsular irrigation system was used.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.